|
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
NOT_RECRUITINGPhase 2Sponsored by IDEAYA Biosciences
No longer actively recruiting
PhasePhase 2
SponsorIDEAYA Biosciences
Started2023-07-03
Est. completion2027-04-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT05907954
Summary
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy * Cohort 3 (patients with small UM tumors) - clinically diagnosed uveal (not iris) melanoma that is \< 4 mm in thickness requiring treatment * Able to dose orally * ECOG Performance status of 0-1 * No other significant underlying ocular disease * Adequate organ function * Not pregnant/nursing or planning to become pregnant. Willing to use birth control Exclusion Criteria: * Previous treatment with a Protein Kinase C (PKC) inhibitor * Concurrent malignant disease * Active HIV infection or Hep B/C * Malabsorption disorder * Unable to discontinue prohibited medication * Impaired cardiac function or clinically significant cardiac disease * Any other condition which may interfere with study interpretation or results
Conditions2
CancerUveal Melanoma
Interventions1
Locations13 sites
HonorHealth Research Institute
(480) 323-1791clinicaltrials@honorhealth.com
Moores Cancer Center
Stanford Cancer Institute
Sarah Cannon Research Institute
Find trials near these locations
Related trials
- Neoadjuvant Darovasertib in Primary Uveal Melanoma — IDEAYA Biosciences
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 2
SponsorIDEAYA Biosciences
Started2023-07-03
Est. completion2027-04-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT05907954